Gastric cancer

Byaibio

Gastric cancer is a major malignancy in which immune evasion, therapeutic resistance, and tumor heterogeneity are prominent biological themes. It is shaped by multiple regulatory layers, including ac129507.1 as a ferroptosis-related lncRNA, cbslr as a metabolism-associated lncRNA, hcp5 as a hypoxia-responsive lncRNA, and hmgb3 aberrant upregulation, while ar is highlighted as a potential prognostic and immune-related therapeutic target. Recent work also links neural and stromal cues to outcome, with high TH+ fiber density and sympathetic nerve infiltration associated with poorer survival and reduced response to immune checkpoint blockade, and nerve-driven cross-talk with pd l1-related pathways or pd l1-enhancing strategies affecting immunotherapy sensitivity. Biomarker and modeling advances include utp4 as an overexpressed prognostic marker whose knockdown suppresses proliferation, migration, and invasion, and a deep learning pathomics signature for prognosis and treatment-response prediction. Therapeutic studies span engineered her2 car t plus IL-12, perioperative durvalumab plus FLOT, and sequencing analyses of immunochemotherapy, reflecting active optimization of multimodal treatment. Spatial multi-omics and multicenter imaging studies are also advancing the dissection of heterogeneity, tertiary lymphoid structures, and resistance mechanisms in gastric cancer.

Immune evasion, neural regulation, and immunotherapy response

  • lncRNA-mediated immune escape, ferroptosis, metabolic reprogramming, and immunotherapy response were reviewed as key mechanisms in gastric cancer immunity. (PMID:41747446)
  • Targeting tumor-associated sympathetic nerves was reported to orchestrate tertiary lymphoid structures and enhance PD-1/PD-L1 blockade efficacy in gastric cancer. (PMID:41850182)
  • Noninvasive imaging of tertiary lymphoid structures was evaluated as a multicenter predictor of immunotherapy response in gastric cancer. (PMID:41642706)
  • Nerve-driven cross-talk between gastric cancer and group 3 innate lymphoid cells was shown to enhance immunosuppression. (PMID:41534088)
  • Targeting the ANXA1/TRKA axis improved immunotherapy sensitivity in neural invasion-positive gastric cancer. (PMID:41954859)

Resistance, prognosis, and biomarker discovery

  • NAT10 was reported to promote cisplatin resistance and immune escape by increasing DUSP1 and PD-L1 expression in gastric cancer. (PMID:41956987)
  • UTP4 was experimentally validated as a novel biomarker; it was overexpressed, associated with poor prognosis, and its knockdown inhibited proliferation, migration, and invasion. (PMID:41822801)
  • A deep learning-based pathomics signature predicted prognosis and treatment response in a multicenter gastric cancer cohort. (PMID:41957258)
  • Multi-omics analysis identified AR as a potential prognostic factor and immune-related therapeutic target in gastric cancer. (PMID:41890218)
  • HMGB3 was reported as aberrantly upregulated in gastric cancer in a broader review of therapy resistance and stemness. (PMID:41930588)

Treatment strategies and clinical optimization

  • PiggyBac-engineered HER2-CAR-T cells potentiated by antigen-induced IL-12 were evaluated for antitumor efficacy against gastric cancer. (PMID:41785602)
  • Perioperative durvalumab plus FLOT improved outcomes in gastric/GEJ cancer. (PMID:41941004)
  • A multicenter propensity score-matched analysis assessed how immunochemotherapy sequence affects overall survival in advanced gastric cancer. (PMID:41941004)
  • A planned systematic review and network meta-analysis will compare overall survival across treatment modalities for gastric cancer. (PMID:41981647)
  • Anti-PD-L1 efficacy was limited by sympathetic nerve infiltration, while adrenergic blockade enhanced response in gastric cancer. (PMID:41850182)

Spatial biology and heterogeneity

  • Spatial multi-omics was highlighted as a high-definition approach for dissecting gastric cancer heterogeneity, biomarkers, and therapy resistance. (PMID:41892326)
  • A multicenter imaging study linked tertiary lymphoid structures with immunotherapy response, supporting spatial immune context as a clinically relevant feature. (PMID:41642706)
  • Neural invasion-positive disease showed distinct immune microenvironment features that influenced immunotherapy sensitivity. (PMID:41954859)
  • The review of spatial multi-omics emphasized applications for optimizing therapeutic efficacy in gastric cancer. (PMID:41892326)